| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 6/6 |
| Financial Health | 5/6 |
| Dividends | 5/6 |
Tibet Rhodiola Pharmaceutical Holding Co. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥47.75 |
| 52 Week High | CN¥64.47 |
| 52 Week Low | CN¥35.04 |
| Beta | 0.93 |
| 1 Month Change | 7.23% |
| 3 Month Change | 10.46% |
| 1 Year Change | -18.47% |
| 3 Year Change | -19.64% |
| 5 Year Change | n/a |
| Change since IPO | -25.41% |
Recent News & Updates
Recent updates
Shareholder Returns
| 600211 | CN Healthcare | CN Market | |
|---|---|---|---|
| 7D | 4.2% | 1.9% | 1.6% |
| 1Y | -18.5% | -32.4% | -15.1% |
Return vs Industry: 600211 exceeded the CN Healthcare industry which returned -32.4% over the past year.
Return vs Market: 600211 underperformed the CN Market which returned -15.1% over the past year.
Price Volatility
| 600211 volatility | |
|---|---|
| 600211 Average Weekly Movement | 5.7% |
| Healthcare Industry Average Movement | 6.8% |
| Market Average Movement | 8.8% |
| 10% most volatile stocks in CN Market | 12.6% |
| 10% least volatile stocks in CN Market | 5.3% |
Stable Share Price: 600211 has not had significant price volatility in the past 3 months.
Volatility Over Time: 600211's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 601 | Yuan Dong Guo | www.xzyy.cn |
Tibet Rhodiola Pharmaceutical Holding Co. engages in the research and development, production, and sale of pharmaceuticals in China and internationally. It offers biological products, Tibetan medicine, Chinese medicine, and chemical medicine products. The company was founded in 1999 and is based in Lhasa, China.
Tibet Rhodiola Pharmaceutical Holding Co. Fundamentals Summary
| 600211 fundamental statistics | |
|---|---|
| Market cap | CN¥11.84b |
| Earnings (TTM) | CN¥800.91m |
| Revenue (TTM) | CN¥3.13b |
14.7x
P/E Ratio3.8x
P/S RatioIs 600211 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 600211 income statement (TTM) | |
|---|---|
| Revenue | CN¥3.13b |
| Cost of Revenue | CN¥158.67m |
| Gross Profit | CN¥2.98b |
| Other Expenses | CN¥2.17b |
| Earnings | CN¥800.91m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 27, 2024
| Earnings per share (EPS) | 3.23 |
| Gross Margin | 94.94% |
| Net Profit Margin | 25.55% |
| Debt/Equity Ratio | 14.8% |
How did 600211 perform over the long term?
See historical performance and comparison